60 Degrees Pharmaceuticals, Inc.
SXTP
Rank in Stocks
#32185
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated... 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Share Price
$0.5462
Last synced: 2026-11-09
Market Cap
$1.92M
Change (1 day)
-8.19%
Change (1 year)
-89.25%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade 60 Degrees Pharmaceuticals, Inc. (SXTP)
Category
Healthcare
EPS for 60 Degrees Pharmaceuticals, Inc. (SXTP)
EPS as of June 2026 TTM: $-6.05
According to 60 Degrees Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-6.05. At the end of 2025 the company had an EPS of $-11.73, an increase over its 2024 EPS of $-74.20.
EPS history for 60 Degrees Pharmaceuticals, Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.05 | -48.42% |
| 2025 | $-11.73 | -84.19% |
| 2024 | $-74.20 | 1,852.63% |
| 2023 | $-3.80 | -11.21% |
| 2022 | $-4.28 | 44.59% |
| 2021 | $-2.96 | 42.31% |
| 2020 | $-2.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -358.84% |
US
|
|
| $-7.07 | 16.86% |
US
|
|
| $-5.29 | -12.56% |
AU
|
|
| $12.88 | -312.89% |
BE
|
|
| $21.56 | -456.36% |
NL
|
Questions about 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS)
What is 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS)?
60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-6.05, as of Jun 2026.
What was 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) was $-11.73, compared with $-74.20 in 2024.
How has 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2020 ($-2.08) and lowest in 2024 ($-74.20).
How does 60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
60 Degrees Pharmaceuticals, Inc.'s earnings per share (EPS) ($-6.05) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.